Inhibrx Biosciences stock rose 9.4% as analyst views stayed mixed

Inhibrx Biosciences stock drew renewed attention after shares rose 9.4 percent in midday trading on Tuesday, November 10, 2026, according to MarketBeat. The move took the shares as high as 91.99 US dollars, while reported volume was about 98 percent below the stock's daily average. MarketBeat said the company had previously closed at 84.52 US dollars.

Analyst Views Remain Divided

MarketBeat described a broad spread in recent research opinions. HC Wainwright began coverage with a buy rating and a 245 US dollar price target, while Weiss Ratings maintained a sell rating, Wall Street Zen moved to strong sell, and Citigroup reiterated market perform.

The resulting consensus was Moderate Buy, with an average target of 197.50 US dollars. Such a wide range of views underlines the sensitivity of the investment case to clinical progress and future financing needs rather than established commercial revenue.

Clinical Programs Drive The Case

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic medicines for cancer and other serious diseases. Its research platform uses protein engineering to design investigational therapies aimed at specific biological targets.

The pipeline includes INBRX-109, an experimental antibody targeting the DR5 receptor, and INBRX-106, an investigational OX40-targeting antibody. Neither candidate is an approved medicine, so trial results and regulatory developments remain central milestones for investors.

Company Profile And Market Position

Based in La Jolla, California, Inhibrx focuses on oncology research and antibody-based drug development. The company operates as a specialized clinical-stage biotech rather than a diversified commercial pharmaceutical group, leaving its valuation closely linked to the progress of its lead programs.

U.S. biotech shares remain sensitive to clinical milestones and risk appetite across the S&P 500, although broader index direction does not determine the outcome of an individual drug-development program.